Enlivex Ltd. (ENLV) Form 6-K — Oct 28, 2026
Enlivex announced that 135 of a planned 182 patients have been randomized and dosed with Allocetra in its Phase 2b trial for moderate-to-severe age-related knee osteoarthritis. Enrollment is actively ongoing at sites in the United States, Denmark and Poland, with topline six-month data expected by mid-2027. The trial builds on positive Phase 1/2a data that supported an FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted in July 2026.
Key figures
- Patients planned
- 182
- Randomization pct
- more than 70%
- Patients randomized
- 135
- Topline data timing
- mid-2027
- Us knee oa patients
- more than 32 million today, projected 78 million by 2040
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.